Dr. Matt Healy is a leader for Booz Allen’s health business, responsible for our work at the Food and Drug Administration (FDA). He has more than 20 years of experience focusing on business optimization, biomedical research, medical product development, and regulatory science not only at the FDA, but also for the Department of Defense (DOD) and pharmaceutical and biotechnology industry clients.
Matt has a deep knowledge and understanding of the FDA’s regulatory review processes for new drugs, biologic products, and medical devices, as well as post-market safety and surveillance programs. In his current role, he leads multidisciplinary teams focused on delivering a broad spectrum of capabilities from analytics to data modernization and digital transformation to optimize FDA’s operations.
Matt has served as a subject matter expert on drug development and regulatory policy for pharmaceutical and biotechnology companies and DOD clients involved in medical product development.
Matt received a Ph.D. in biochemistry and molecular biology from Johns Hopkins University, an M.B.A. from the University of Maryland, and a B.A. from the University of Virginia.
